
Q/C Technologies Amends Preferred Stock and Warrants with PharmaCyte
Q/C Technologies, Inc. has entered into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc., which is a significant holder of the company's Series G and Series H convertible preferred stock. The agreement amends the terms of the Series G and Series H Certificates of Designations, specifically addressing amendment provisions and beneficial ownership limitations for PharmaCyte. Additionally, the Series G Long-Term Warrants held by PharmaCyte have been amended to modify their amendment provisions and beneficial ownership limitations. A separate amendment to the Series H Certificate of Designations extends the maturity date of the Series H Preferred Stock from March 2, 2027, to September 2, 2027.
Key Highlights
- Q/C Technologies and PharmaCyte Biotech entered into an Omnibus Amendment Agreement.
- Amendments were made to the Series G and Series H Certificates of Designations regarding amendment provisions and beneficial ownership limitations.
- Series G Long-Term Warrants held by PharmaCyte were amended concerning amendment provisions and beneficial ownership limitations.
- The maturity date of Series H Preferred Stock was extended from March 2, 2027, to September 2, 2027.
Price Impact
More from QCLS
More in Corporate Action